Organ‐on‐chips can highly simulate the complex physiological functions of organs, exhibiting broad application prospects in developmental research, disease simulation, as well as new drug research and development. However, there is still less concern about effectively constructing cochlea‐on‐chips. Here, a novel cochlear organoids‐integrated conductive hydrogel biohybrid system with cochlear implant electroacoustic stimulation (EAS) for cochlea‐on‐a‐chip construction and high‐throughput drug screening, is presented. Benefiting from the superior biocompatibility and electrical property of conductive hydrogel, together with cochlear implant EAS, the inner ear progenitor cells can proliferate and spontaneously shape into spheres, finally forming cochlear organoids with good cell viability and structurally mature hair cells. By incorporating these progenitor cells‐encapsulated hydrogels into a microfluidic‐based cochlea‐on‐a‐chip with culture chambers and a concentration gradient generator, a dynamic and high‐throughput evaluation of inner ear disease‐related drugs is demonstrated. These results indicate that the proposed cochlea‐on‐a‐chip platform has great application potential in organoid cultivation and deafness drug evaluation.

中文翻译：

---

电声响应耳蜗芯片

器官芯片可以高度模拟器官的复杂生理功能，在发育研究、疾病模拟以及新药研发等方面展现出广阔的应用前景。然而，对于有效构建片上耳蜗的关注仍然较少。在这里，提出了一种新型耳蜗类器官集成导电水凝胶生物混合系统，具有耳蜗植入电声刺激（EAS），用于耳蜗芯片构建和高通量药物筛选。受益于导电水凝胶优异的生物相容性和电学性能，与人工耳蜗EAS一起，内耳祖细胞可以增殖并自发成形为球体，最终形成具有良好细胞活力和结构成熟的毛细胞的耳蜗类器官。通过将这些祖细胞封装的水凝胶整合到带有培养室和浓度梯度发生器的基于微流体的芯片耳蜗中，可以对内耳疾病相关药物进行动态和高通量评估。这些结果表明，所提出的耳蜗芯片平台在类器官培养和耳聋药物评价方面具有巨大的应用潜力。